A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Transplantation and Cellular Therapy（2023）
关键词
cytomegalovirus,letermovir,prophylaxis,double-blind,placebo-controlled,post-transplant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要